Pfizer down as anti-smoking drug probed by FDA

Filed under: Bad news, Products and services, Pfizer (PFE), Options, Technical AnalysisPfizer Inc. (NYSE: PFE) stock is falling this morning as the FDA said late yesterday afternoon that it will investigate reports of mood disorders, violent behavior, and suicidal reports among patients taking Chantix, an anti-smoking drug made by PFE. The FDA is still collecting information on the drug, but advised doctors to exercise caution in prescribing the drug. Chantix was approved for use by the FDA last year, and has generated sales in excess of $100 million for PFE. PFE responded Tuesday that there is no scientific evidence establishing a causal relationship between Chantix and these symptoms. If you think this stock won't be rising too far in the coming months, then it could be a good time to lo